PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Montelukast - Asthma
PAD Profile : Montelukast - Asthma Important
Keywords :
Leukotriene receptor antagonists, LTRAs
Brand Names Include :
Singulair
Important Information :
https://www.gov.uk/drug-safety-update/montelukast-singulair-reminder-of-the-risk-of-neuropsychiatric-reactions
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Fostair NEXThaler (beclometasone and formoterol)
- Theophylline
- Easyhaler (Salbutamol)
- Clenil Modulite (beclometasone)
- Easyhaler (Beclometasone)
- Easyhaler (Budesonide)
- Fostair (Beclometasone and formoterol)
- Budelin Novolizer (budesonide)
- Dupilumab
- Airflusal (Salmeterol/Fluticasone) MDI
- Aerivio Spiromax (Fluticasone/Salmeterol) DPI
- Ventolin Accuhaler (salbutamol)
- Sereflo Ciphaler (Salmeterol / Fluticasone) DPI
- Campona Airmaster (Salmeterol / Fluticasone) DPI
- Salbutamol
- Terbutaline sulphate
- Budesonide
- Salamol Easi-Breathe
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
06 March 2019
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Montelukast may be an appropriate first-line addition to ICS (particularly if atopy or allergic component).
Prescribe generically (the brand Singulair was assigned a BLACK traffic light status by the PCN in May 2017)
The guidelines for Asthma can be found below
Associated BNF Codes
03. Respiratory System
03.03.02. Leukotriene receptor antagonists